Mesoblast Limited (NASDAQ:MESO) has been given a consensus recommendation of “Hold” by the six ratings firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $11.17.

Several research analysts have recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Mesoblast Limited in a research note on Thursday, June 8th. Credit Suisse Group set a $11.00 target price on shares of Mesoblast Limited and gave the company a “hold” rating in a research note on Tuesday, July 18th. BidaskClub lowered shares of Mesoblast Limited from a “sell” rating to a “strong sell” rating in a research note on Friday, July 28th. Zacks Investment Research raised shares of Mesoblast Limited from a “sell” rating to a “buy” rating and set a $10.00 target price on the stock in a research note on Tuesday, May 23rd. Finally, Maxim Group set a $14.00 target price on shares of Mesoblast Limited and gave the company a “buy” rating in a research note on Thursday, May 25th.

Shares of Mesoblast Limited (NASDAQ MESO) opened at 7.13 on Friday. The firm’s market capitalization is $567.15 million. The company’s 50-day moving average is $7.48 and its 200 day moving average is $8.17. Mesoblast Limited has a 1-year low of $4.01 and a 1-year high of $12.50.

TRADEMARK VIOLATION NOTICE: “Mesoblast Limited (NASDAQ:MESO) Given Consensus Recommendation of “Hold” by Brokerages” was first posted by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.dailypolitical.com/2017/08/13/mesoblast-limited-nasdaqmeso-given-consensus-recommendation-of-hold-by-brokerages.html.

An institutional investor recently raised its position in Mesoblast Limited stock. Princeton Capital Management Inc. boosted its stake in Mesoblast Limited (NASDAQ:MESO) by 15.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 155,700 shares of the company’s stock after buying an additional 20,945 shares during the period. Princeton Capital Management Inc. owned 0.20% of Mesoblast Limited worth $1,398,000 at the end of the most recent quarter. 2.91% of the stock is owned by institutional investors and hedge funds.

Mesoblast Limited Company Profile

Receive News & Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related companies with MarketBeat.com's FREE daily email newsletter.